US law & policy — Psychedelic research and access (hub)
Federal scheduling, state experiments, and how to read policy news alongside the science — in one place, without legal advice.
What this hub covers
Psychedelic substances sit at the intersection of federal drug control, emerging medical evidence, and fast-moving state policy. This page is a map of frameworks, not legal advice. Always consult qualified counsel for your situation and jurisdiction.
Federal (United States) — big picture
Most classic psychedelics are regulated under the Controlled Substances Act (CSA). DEA administers registration for research, manufacturing, and (where applicable) practice under federal rules. FDA evaluates safety and effectiveness for new drug applications; state laws do not replace the need for federal approval where a drug is intended for interstate use as a licensed medicine.
Our briefings surface material developments from the Federal Register, agency guidance, and dockets. Use them together with the evergreen research & policy landscape for orientation.
State and local
States and cities have taken divergent paths: research programs, decriminalization, regulated adult access, and ballot initiatives. A rule that applies in one state may not apply next door. We track noteworthy state-level signals in analysis and, where useful, in our policy calendar.
For compound-specific and condition-specific educational overviews, see the Guides & explainers index. Legal status in your location must be verified with primary sources and counsel.
How this ties to the daily feed
Time-stamped analyses explain what changed in a given week. This hub explains where those changes sit in the overall regulatory and research environment. The two are meant to be read together.
Not legal or medical advice
Nothing on this site is a substitute for professional legal or clinical advice. We summarize public sources to support informed reading and research literacy.